Imepitoin
Imepitoin is a centrally acting antiepileptic drug primarily used in veterinary medicine for the management of idiopathic epilepsy in dogs, as well as for the treatment of noise phobia. Unlike traditional antiepileptics like phenobarbital, it has a lower risk of hepatotoxicity and does not typically induce liver enzymes to the same extent. **Clinical Pearl:** Imepitoin is often preferred for dogs with mild to moderate idiopathic epilepsy due to its favorable side effect profile, but it may not be sufficient as a monotherapy for severe or cluster seizures.
Mechanism: Imepitoin inhibits seizures via potentiation of the **GABA_A** receptor-mediated inhibitory effects on the neurons. It acts as a low-affinity partial agonist at the benzodiazepine site of the GABA_A receptor → hyperpolarization of the neuronal membrane → decreased neuronal excitability. Imepitoin also has a weak **calcium-channel blocking effect**, which may contribute to its anticonvulsive properties.
Routes of administration
Contraindications
- Severely impaired hepatic function
- Severe renal disorders
- Severe cardiovascular disorders
- Status epilepticus
- Cluster seizures (as primary monotherapy)
Adverse effects
- Polyphagia
- Hyperactivity
- Polyuria
- Polydipsia
- Somnolence
- Hypersalivation
- Emesis
- Ataxia
Drug interactions
- Phenobarbital · May have additive CNS depressant effects · moderate
- Other CNS depressants · Additive sedation and CNS depression · moderate
Monitoring
- Seizure frequency and severity
- Routine blood work (CBC, serum biochemistry) periodically
Overdose
Overdosage is generally well tolerated up to 5 times the recommended dose. Clinical signs of overdose may include severe **ataxia**, **somnolence**, **salivation**, and **vomiting**. **Clinical Pearl:** Treatment is largely supportive and symptomatic, as there is no specific antidote. Due to its rapid elimination, signs usually resolve quickly once the drug is discontinued or metabolized.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.